Need Help?

Ewing's Sarcoma RNA-Seq

28 Pretreated Ewing sarcoma tumor blood samples were collected from the Hospital for Sick Children (SickKids) and Mount Sinai Hospital in Toronto, Canada in accordance with each institution’s Research Ethical Board (REB) guidelines. Detailed clinical information (age at presentation, gender, tumor site, stage, etc.) were obtained from the corresponding institutional tumor banks. Transcriptome (RNA-Seq) sequencing was performed using established protocols on Illumina instruments.

Request Access

The Hospital for Sick Children policy

DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom Shlien Lab, at The Hospital for Sick Children grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: Shlien Lab, at The Hospital for Sick Children and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Hospital for Sick Children 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify EGA within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify EGA prior to any significant changes to the protocol for the Project. 14. The User Institution will notify EGA as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. EGA may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than EGA. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001003062 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00002032320 fastq.gz 11.4 GB
EGAF00002032321 fastq.gz 10.9 GB
EGAF00002032322 fastq.gz 12.7 GB
EGAF00002032323 fastq.gz 13.2 GB
EGAF00002032324 fastq.gz 8.8 GB
EGAF00002032325 fastq.gz 8.7 GB
EGAF00002032326 fastq.gz 6.7 GB
EGAF00002032327 fastq.gz 6.8 GB
EGAF00002032328 fastq.gz 6.0 GB
EGAF00002032329 fastq.gz 6.0 GB
EGAF00002032330 fastq.gz 10.6 GB
EGAF00002032331 fastq.gz 11.1 GB
EGAF00002032332 fastq.gz 10.6 GB
EGAF00002032333 fastq.gz 11.3 GB
EGAF00002032334 fastq.gz 10.9 GB
EGAF00002032335 fastq.gz 11.4 GB
EGAF00002032336 fastq.gz 11.4 GB
EGAF00002032337 fastq.gz 12.0 GB
EGAF00002032338 fastq.gz 12.1 GB
EGAF00002032339 fastq.gz 11.8 GB
EGAF00002032340 fastq.gz 11.4 GB
EGAF00002032341 fastq.gz 11.5 GB
EGAF00002032342 fastq.gz 11.7 GB
EGAF00002032343 fastq.gz 12.1 GB
EGAF00002032344 fastq.gz 12.0 GB
EGAF00002032345 fastq.gz 12.0 GB
EGAF00002032346 fastq.gz 11.9 GB
EGAF00002032347 fastq.gz 11.7 GB
EGAF00002032348 fastq.gz 10.8 GB
EGAF00002032349 fastq.gz 10.6 GB
EGAF00002032350 fastq.gz 10.9 GB
EGAF00002032351 fastq.gz 11.3 GB
EGAF00002032352 fastq.gz 10.9 GB
EGAF00002032353 fastq.gz 11.1 GB
EGAF00002032354 fastq.gz 11.4 GB
EGAF00002032355 fastq.gz 11.2 GB
EGAF00002032356 fastq.gz 6.9 GB
EGAF00002032357 fastq.gz 6.9 GB
EGAF00002032358 fastq.gz 6.3 GB
EGAF00002032359 fastq.gz 6.3 GB
EGAF00002032360 fastq.gz 10.2 GB
EGAF00002032361 fastq.gz 10.2 GB
EGAF00002032362 fastq.gz 8.1 GB
EGAF00002032363 fastq.gz 8.1 GB
EGAF00002032364 fastq.gz 12.1 GB
EGAF00002032365 fastq.gz 11.9 GB
EGAF00002032366 fastq.gz 6.5 GB
EGAF00002032367 fastq.gz 6.6 GB
EGAF00002032368 fastq.gz 6.9 GB
EGAF00002032369 fastq.gz 6.9 GB
EGAF00002032370 fastq.gz 6.3 GB
EGAF00002032371 fastq.gz 6.4 GB
EGAF00002032372 fastq.gz 7.7 GB
EGAF00002032373 fastq.gz 7.8 GB
EGAF00002032374 fastq.gz 5.9 GB
EGAF00002032375 fastq.gz 5.9 GB
56 Files (541.1 GB)